Global Lung Transplant Therapeutics Market, By Product (Immunosuppressant Drugs, Organ Preservation Products, Tissue Product, Others), Indication (Cystic Fibrosis, Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), Interstitial Pulmonary Fibrosis, Pulmonary Hypertension, Primary Pulmonary Arterial Hypertension, Emphysema, Sarcoidosis, Septic Lung Disease, Others), Type (Cadaveric Lung transplant, Living Lung Transplant), Technique (Single-Lung,Transplant (SLT), Double Lung Transplant, Bilateral Lung Transplant (BLT), Heart-Lung Transplant), Patient Demographics (Adults, Geriatric, Paediatric), End User (Hospital, Transplant centres, Speciality Centres and Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights: Global Lung Transplant Therapeutics Market
The global lung transplant therapeutics market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.8% in the forecast period of 2022 to 2029 and is expected to reach USD 218.10 million by 2029. The launch of new products by major market players is expected to drive the market's demand in the forecast period.
A lung transplant is surgery done to remove a diseased lung and replace it with a healthy lung from another person. Lung transplants surgery can be performed on people of almost all ages, from newborns to adults up to age 65 and sometimes even later. A lung transplant is for people who have tried other medications or treatments, but their underlying conditions have not improved sufficiently or worsened over time. Depending on the patient's medical condition, a lung transplant may involve replacing one lung or both. The lungs may be transplanted with a donor's heart in some situations. A lung transplant can significantly improve patient health and quality of life.
Increasing drug approvals, rise in clinical trials, high incidence of chronic disease, and some ongoing research to increase the therapeutics application is expected to drive the market's growth. However, fewer donors for organ donation and the high cost of lung transplant procedures may hamper the market growth. Meanwhile, rising healthcare spending, strategic initiatives by market players, technological advancements in lung transplantation may create opportunities for market growth. Stringent regulatory framework and complications associated with lung transplantation may challenge the market growth.
The global lung transplant therapeutics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief; our team will help you create a revenue impact solution to achieve your desired goal.
Global Lung Transplant Therapeutics Market Scope and Market Size
The Global lung transplant therapeutics market is segmented into product, indication, type, technique, patient demographics, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the global lung transplant therapeutics market is segmented into immunosuppressant drugs, tissue products, organ preservation products, and others. In 2022, the immunosuppressant drugs segment is expected to dominate the global lung transplant therapeutics market due to the increase in the consumption of immune system suppressant drugs because of their wider benefit and effective profile by patients to avoid lung rejection and the wide availability of these drugs in hospitals and retail stores.
- On the basis of type, the global lung transplant therapeutics market is segmented into cadaveric lung transplantation and living lung transplantation. In 2022, the cadaveric lung transplantation segment is expected to dominate the global lung transplant therapeutics market due to increased awareness regarding organ donation and its applications.
- On the basis of indication, the global lung transplant therapeutics market is segmented into chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, septic lung disease, pulmonary hypertension, cystic fibrosis, interstitial pulmonary fibrosis, emphysema, primary pulmonary arterial hypertension sarcoidosis, and others. In 2022, the cystic fibrosis segment is expected to dominate the global lung transplant therapeutics market due to the increase in the patient population of cystic fibrosis patients in the region.
- On the basis of technique, the global lung transplant therapeutics market is segmented into single-lung transplantation, bilateral-lung transplantation, heart-lung transplantation, and double lung transplantation. In 2022, the single-lung transplantation (SLT) segment is expected to dominate the global lung transplant therapeutics market due to the highest number of lung transplantation procedures in North America (55%) and Europe (36%).
- On the basis of patient demographics, the global lung transplant therapeutics market is segmented into adult, pediatric, and geriatric. In 2022, the adult segment is expected to dominate the global lung transplant therapeutics market due to the increase in health complications observed in the world population, China and India of the Asia-Pacific region contributes the largest population.
- On the basis of end users, the global lung transplant therapeutics market is segmented into hospital, transplant centers, specialty centers, and others. In 2022, the hospital segment is expected to dominate the global lung transplant therapeutics market due to new hospital advancements for effective surgeries under-skilled doctors and increased awareness regarding organ donation, registration, and chronic diseases.
Global Lung Transplant Therapeutics Market Country Level Analysis
The lung transplant therapeutics market is analyzed, and market size information is provided based on product, type, indication, technique, patient demographics, and end users.
The countries covered in the global lung transplant therapeutics market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East and Africa.
In the U.S., an increase in drug approvals by market players for new and effective treatment is expected to drive market growth. Germany is expected to dominate the market due to an increase in organ transplant procedures. China is expected to dominate due to the largest population in the world, including the biggest geriatric population.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Strategic initiatives by market players in collaboration with government bodies for better data and the rising in awareness of organ transplant importance and its safety which is expected to escalate the market growth in the forecast period
The global lung transplant therapeutics market also provides you with detailed market analysis for every country's growth in the lung transplant industry with sales, the impact of advancement in the lung transplant technology, and changes in regulatory scenarios with their support for the lung transplant therapeutics market. The data is available for the historical period 2011 to 2020.
Competitive Landscape and Market Share Analysis
The global lung transplant therapeutics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points are only related to the company's focus on the global lung transplant therapeutics market.
Some of the major players operating in this market are Astellas Pharma, Inc., TransMedics, Dr. Reddy's Laboratories Ltd., F.Hoffmann-La Roche Ltd., Hikma Pharmaceuticals PLC, Apotex Inc., XVIVO, Novartis AG, BioLife Solutions, Viatris Inc., and Pfizer Inc., among others.
Various market players provide better safety and effective treatments, which also accelerate the global lung transplant therapeutics market.
For instance,
- In April, Astellas Pharma Inc. received the "2021 Award for Excellence in Corporate Disclosure" from the Securities Analysts Association of Japan. This helped company in strengthening its position over the market, gaining more customer base
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other market players enhance the company in the global lung transplant therapeutics market, which also benefits the organization to improve its offering.
SKU-